Opinion - Pharmaceutical Executive


Analysis and interpretation of the issues facing Pharma: healthcare policy, public opinion, social trends, globalization, and more.

Innovating Around Innovation

September 1, 2011

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Get Back in the Box!

September 1, 2011

Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.

Complex Biologics: The View from Teva

September 1, 2011

Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.

Europe in HTA Gridlock

August 1, 2011

HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.

Giving Press Releases New Legs

August 1, 2011

Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed

UK Stakeholders Have Their Say on Value-Based Pricing

May 1, 2011

The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance

Restoring Public Trust in Pharma

April 1, 2011

GSK's Deirdre Connelly puts the focus on four steps to cement a new compliance culture

The Orphan Opportunity

September 1, 2008

The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains

Relaunching Reform

June 1, 2008

This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change


Click here